Trial Profile
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mardepodect (Primary)
- Indications Huntington's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms AMARYLLIS
- Sponsors Pfizer
- 09 Oct 2018 Results presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders
- 12 Oct 2016 Status changed from recruiting to completed.
- 27 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.